Shopping cart ITEMS
 modern scholarly publishers in the finest tradition
Login Register
Home
Books
Journals
References
A-Z Index
Author Index
For Our Authors
User Area
Shopping Cart
Contact
Electronic Data Center

Critical Reviews™ in Immunology

 

ISSN for PRINT: 1040-8401

Institutional price:

$831.00

Issues per year:

6

For Online Access

Best Paper Award Selection - Editorial Board Site

Add subscription to shopping cart

2008, Volume28

Issue 2

  91 pages  

   

click 'Save as...' here to save XML metadata

Issue price - $166.00  

Add to shopping cart

  • Immune Responses Against Persistent Viral Infections: Possible Avenues for Immunotherapeutic Interventions
  • Shinichiro Fuse
    Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756

    Michael J. Molloy
    Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756

    Edward J. Usherwood
    Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756


    ABSTRACT

    Persistent viral infections present a significant threat to society, and treatment options for infected individuals are in urgent demand. During viral persistence, the balance between the virus and the host immune response is crucial. The immune system keeps the virus in check, and the virus counters by evading the immune response to avoid clearance, ultimately tipping the balance in favor of the virus and causing disease in many cases. Thus, efforts to tip the balance in favor of the host through immunotherapy holds promise for establishing control of viral replication. However, in most persistent viral infections, the continuous presence of the viral antigen renders virus-specific T cells to become dysfunctional. These differences can range from severe functional impairments in high-load persistent infections, to more subtle changes in infections with a lower virus burden. Recent work has shed light on immunoregulatory molecules or cytokines that affect viral persistence and/or T-cell function, and interventions that modulate these factors have led to effective viral control in experimental models. Exploitation of these experimental therapies may lead to treatments that would be of great clinical benefit to patients suffering from persistent virus infections, such as HIV, HBV, or HCV, or the herpesviruses CMV and EBV.

    Download article, 159-183 pages

    Article price - $45.00  

    Add to shopping cart

    << Previous article  

    Designed by offsiteteam Designed by offsiteteam Designed by offsiteteam
    Begell House Inc.
    50 Cross Highway,
    Redding, CT 06896
    TEL (203) 938 1300
    FAX (203) 938 1304
    orders@begellhouse.com